HARRISBURG, Pa. (AP) — Drugmaker Eli Lilly and Co. (LLY) said Friday that it will build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments. Indianapolis-based Eli Lilly, maker of weight-loss treatment Zepbound and diabetes drug Mounjaro, is in the midst of a broader domestic expansion that includes new plants it has announced in Texas, Virginia and Alabama. Another facility is under construct ...

WASHINGTON, Jan 30 (Reuters) - Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, ​its fourth new site in an effort to expand ‌U.S. production and bolster medical supply chains. The $3.5 billion plant will make Lilly's injectable ‌weight-loss medications, including retatrutide, the company said in a statement. That next-generation obesity drug has outperformed Lilly's blockbuster drug Zepbound. Drugmakers are rushing to expand U.S. production as Pr ...

Core Insights - Eli Lilly announced the construction of a new pharmaceutical manufacturing facility in Pennsylvania, marking its fourth new site aimed at expanding U.S. production and strengthening medical supply chains [1] Company Expansion - The new facility in Pennsylvania is part of Eli Lilly's broader strategy to enhance its manufacturing capabilities within the United States [1] - This initiative reflects the company's commitment to bolstering domestic production and ensuring a robust supply chain for medical products [1] Industry Impact - The establishment of additional manufacturing sites by Eli Lilly is indicative of a growing trend in the pharmaceutical industry to localize production and mitigate supply chain vulnerabilities [1] - This move may influence other companies in the sector to consider similar expansions to enhance their operational resilience [1]

此前市场消息称，该每日一次服用的GLP-1类药物在上市首周便获得18,410张处方，而在第二个完整销 售周处方量突破1.6万张，增长势头迅速。 过去两年，诺和诺德股价在2024和2025年大幅回落，与礼来因抢占约60%的肥胖症药物市场份额而实现 的强劲上涨形成鲜明对比。不过，随着Wegovy口服药快速放量，诺和诺德正在重新夺回投资者信心。 与此同时，礼来仍在等待其口服减肥药orforglipron的FDA审批结果，市场竞争格局或将在未来数月进一 步演变。 在经历连续两年股价下跌后，丹麦制药巨头诺和诺德(NVO.US)在新年伊始迎来强劲反弹，凭借其口服 减肥药Wegovy片剂的亮眼处方表现，今年以来股价走势明显跑赢主要竞争对手礼来(LLY.US)。 数据显示，诺和诺德今年迄今股价累计上涨约16%，而礼来股价同期下跌约4%。这一表现逆转主要源 于诺和诺德在口服减肥药市场的"先发优势"。美国监管机构FDA于去年12月批准Wegovy片剂上市，使 其在本月初正式进入市场，成为首款获批的口服肥胖症药物。 最新处方数据进一步凸显其市场热度。媒体周五援引医疗数据分析机构IQVIA的数据报道称，截至1月 23日当周，Wego ...

Core Viewpoint - Eli Lilly is investing over $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, aimed at producing next-generation obesity drugs, including the experimental drug retatrutide, which has shown significant weight loss results in late-stage trials [1][3]. Group 1: Investment and Expansion - The new Pennsylvania facility is part of a broader strategy, with Lilly planning to invest at least $27 billion in new U.S. manufacturing facilities, following $23 billion in investments since 2020 [2]. - The construction of the Pennsylvania plant is expected to begin this year, with operations slated to start in 2031 [3]. - The new site will create 850 permanent jobs and 2,000 construction jobs in the area [7]. Group 2: Product Development and Market Position - Retatrutide is a key component of Lilly's long-term obesity strategy, complementing its existing injection Zepbound and an upcoming obesity pill [3]. - Health experts believe retatrutide's mechanism, which targets three gut hormones, may provide greater weight loss benefits for patients with severe obesity compared to existing treatments [4]. - Lilly has secured a majority share in the GLP-1 market, overtaking its rival Novo Nordisk, which is launching the first-ever GLP-1 pill for obesity this month [5]. Group 3: Production Capacity and Market Dynamics - The pharmaceutical industry is increasing production capacity in the U.S. due to previous supply shortages and potential tariffs on imported pharmaceuticals [6]. - Recent voluntary drug pricing deals have alleviated concerns about tariffs for companies like Lilly and Novo, exempting them from levies for three years [6].

Core Insights - The region is enhancing its position as a manufacturing hub through increased investments and tax incentives for corporate investors [1] Group 1 - The focus is on attracting larger investments to bolster the manufacturing sector [1] - Corporate investors are being offered more tax perks to encourage investment [1]

Analysts on Wall Street project that Eli Lilly (LLY) will announce quarterly earnings of $6.99 per share in its forthcoming report, representing an increase of 31.4% year over year. Revenues are projected to reach $17.87 billion, increasing 32.1% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 8.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ti ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Eli Lilly ( LLY ) entered 2026 with strong momentum across the board. Its share price has ...

Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going?Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines.Under the terms of the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 ...

U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country. ...